Canine Atopic Dermatitis Market Size – By Product, By Route of Administration, By Distribution Channel – Global Forecast, 2025 – 2034

Canine Atopic Dermatitis Market Size

The global canine atopic dermatitis market was valued at USD 1.4 billion in 2024 and is estimated to grow at a CAGR of 8.9% from 2025 to 2034. This market has seen a plateau increase owing to the fact that the number of dogs suffering with atopic dermatitis is on the rise and there’s focus on the healthcare of companion animals. The market growth is strongly aligned with the rising wellness demands from pet owners, which is reflected by the growth in the advanced veterinary dermatology drugs market.
 

The increase in the size of the market can further be attributed to the advancement in veterinary medicine. Effective and safe treatments for the disease, including monoclonal antibodies: Lokivetmab/Cytopoint and Oclacitinib/Apoquel, have gained acceptance. Most importantly, these treatments have already been shown to reduce pruritus (itching) and inflammation, making them even more in demand. Also, in emerging regions, pricy medicine along with greater understanding of the need for taking care of shelter pets is creating a boom in investment focus around pet care and specialized veterinary medicine, thereby increasing the overall market increase.

Canine atopic dermatitis is a chronic inflammatory skin disease in dogs caused by hypersensitivity to environmental allergens such as pollen, dust mites, mold, or certain foods. This condition that leads to consistent scratching, inflammation, and repeated infection of the skin or ears. It is one of the most commonly encountered skin conditions in dogs and usually tends to occur in breeds such as Retrievers, Terriers, and Bulldogs.
 

Canine Atopic Dermatitis Market Trends

The market is being spurred on by the increasing domestication of pets and the rise in pet ownership.
 

• Alongside the rising population of individuals and families getting pets, there is also increasing need for advanced veterinary services and specialized techniques to deal with issues such as atopic dermatitis.
   
• For instance, approximately 900 million pet dogs exist in the world, highlighting the prominence of dogs as pets globally.
   
• Pet owners are spending more on health care options for their pets as they see them as part of the family. Such expectations set on pet health have catered for the need in the market and changed with the introduction of innovative therapies to control atopic dermatitis in dogs. The adoption of allergen-specific immunotherapy, monoclonal antibodies and specialized dermatological products for dogs are used to manage atopic dermatitis in dogs.
   

Canine Atopic Dermatitis Market Analysis

Based on product, the market is segmented into glucocorticoids, antihistamines, immunosuppressants, mAbs, and other products. The glucocorticoids segment held highest market share and was valued at USD 477.1 million in 2024.
 

• Especially for severe and acute cases, glucocorticoids including prednisone and dexamethasone, give quick and rapid relief for inflammation, for which they are the go-to guide practitioners.
   
• Moreover, the newer treatments such as monoclonal antibodies (Lokivetmab) or oral JAK inhibitors (oclacitinib) are more expensive compared to the glucocorticoids, thus allowing for adoption of these medications in areas with minimal veterinary healthcare facilities or low endorsement of pet insurance.
   
• In addition, high availability of glucocorticoids in veterinary pharmacy hospitals, retail pharmacies, and online stores, ensures easy access, further strengthening their market share and solidifies their role as a cornerstone treatment for canine atopic dermatitis.
   

Based on the route of administration, the global canine atopic dermatitis market is divided into oral, topical, and injectable. The oral segment dominated the market with 47.2% market share in 2024.
 

• The orally taken primary therapies such Oclacitinib (Apoquel) or glucocorticoids, including prednisone, are easier to use and manage, which is why pet owners prefer them. Their ease of use facilitates adherence to treatment and results in differential compliance, thus increasing their acceptance.
   
• Most oral treatments provide relief of major symptoms such as pruritus and inflammation within a few hours to days. This rapid action makes them a favorable option for both short-term flare management and chronic disease control.
   
• Oral therapies have both a proven track record of efficacy and safety. The marketed drugs like oclacitinib are specifically designed to target inflammatory pathways, providing effective and targeted relief, further driving their demand.
   
• These factors collectively drive the growth of the oral segment in the global market.

Based on distribution channel, the market is classified into veterinary hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment accounted for highest market share in 2024 and grow at 8.7% CAGR over the coming years.
 

• Retail pharmacies occupy a large portion of the canine atopic dermatitis market due to their widespread accessibility, easy to obtain and dispense, and pet ownership is increasing.
   
• These pharmacies form a major route for dispensing topical and oral medicines, along with other treatments as instructed by the veterinarian for atopic dermatitis in dogs.
   
• Further, the increasing use of topical and other over-the-counter medications for atopic dermatitis further cements the position of retail pharmacies in this market.

The U.S. canine atopic dermatitis market in 2024 was valued at USD 528 million and is expected to reach USD 1.2 billion by 2034.
 

• The U.S. market holds a significant share in the global market due to the increasing cases of atopic dermatitis in dogs and the awareness of people toward pet healthcare.
   
• The market is additionally driven by the increasing adoption of advanced veterinary diagnosis and therapy and the strong presence of strategic participants with innovative treatment solutions.
   

In the years to come, the German canine atopic dermatitis market is poised for substantial growth.
 

• Germany's pharmaceutical sector has developed a solid footing, particularly in veterinary medicine, which is matched by active supply of R&D, new products, as well as distribution of therapies.
   
• Furthermore, positive governmental action and strict regulations concerning the veterinary pharmaceuticals in the country guarantees the rendering of safe and efficacious therapies, which enhances the development of the market.
   
• Additionally, there has been increase spending on skin disorders, especially pet atopic dermatitis due to more focus given by pet owners on their wellbeing and the bond that exists with their dogs which is now being regarded as a family member.
   

During the projection period, China canine atopic dermatitis market is anticipated to grow at a healthy pace.
 

• The changing demographic in China, with a large and growing middle-class population and higher disposable income, enables more pet owners to afford expensive atopic dermatitis treatments such as monoclonal antibodies and oral JAK inhibitors.
   
• The growth of online pharmacies for animals and e-commerce businesses facilitates easy access to medicines and advanced treatments for pets in both cities and countryside, which aids the market growth.
   

The market for canine atopic dermatitis in Brazil is forecasted to register significant growth throughout the forecast period.
 

• Brazil has one of the largest pet dog populations in relation to its global population, which can be attributed to the culture of having pets. More people getting dogs leads to more units of veterinary care, including the treatment of pet atopic dermatitis.
   
• In addition, the ongoing trend of pet humanization has increased the expenditure on pets’ overall healthcare services including dermatological ailments such as canine atopic dermatitis which positively improves the growth of the market.
   

Saudi Arabia is expected to see positive tendencies in the canine atopic dermatitis market in the future.
 

• Increasing affluence of the Saudi population along with treating pets as part of the family, which translates in increased expenditure on animal health and especially on chronic dog atopic dermatitis treatment.
   
• Moreover, the astonishing rise of e-commerce platforms that market veterinary medicines and supplies further facilitates treatment for animal owner in Saudi Arabia.
   
• Therefore, all these factors combined help grow the market of canine atopic dermatitis in Saudi Arabia.
   

Canine Atopic Dermatitis Market Share

The landscape of the market comprises a large number of domestic and international pharmaceutical firms. Monoclonal antibodies such as Lokivetmab and JAK inhibitors like Oclacitinib are exemplary CAD treatments developed by these major players in the industry. These companies are enhancing their product offerings and market presence through partnerships, research agreements, and merger and acquisitions activities to expand their reach.
 

Canine Atopic Dermatitis Market Companies

Few of the prominent players operating in the canine atopic dermatitis industry include:

• AB Science
• Boehringer Ingelheim
• Ceva
• Dechra Veterinary Products
• Elanco
• Kindred Biosciences
• Nextmune (Vimian)
• Phibro Animal Health Corporation
• Toray Industries
• Vetoquinol
• Virbac
• Zoetis

USPs for top players:

• Investing in clinical studies and developing innovative therapies with few adverse effects.
   
• Market entry through mergers and acquisitions to strengthen the market and reach new clients.
   
• Collaborations with animal hospitals and research centers to enhance product development and distribution.
   

Canine Atopic Dermatitis Industry News

• In September 2024, Elanco Animal Health Incorporated announced that the U.S. Food and Drug Administration (FDA) approved Zenrelia, a safe and highly effective once-daily oral JAK inhibitor designed to control pruritus (itching) associated with allergic dermatitis and manage atopic dermatitis in dogs aged 12 months or older. The approval allowed the company to expand its product portfolio and strengthen its position in the growing canine dermatological treatment market.
   

The canine atopic dermatitis market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Glucocorticoids
• Antihistamines
• Immunosuppressants
• mAbs
• Other products

Market, By Route of Administration

• Oral
• Topical
• Injectable

Market, By Distribution Channel

• Retail pharmacies
• Veterinary hospital pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE